Replimune to resubmit melanoma drug after FDA’s Makary leaves
Thomas Fuller | Lightrocket | Getty Images Replimune plans to resubmit its melanoma drug to the Food and Drug Administration for review after a leadership exodus at the agency, the company said Friday. The FDA […]
